1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Tirzepatide |
| brand | String | Mounjaro (T2DM), Zepbound (obesity, OSA) |
| structure | File | |
| classes | List of String, delimiter: , | [[GLP-1 receptor agonist]] · [[GIP receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · [[Anti-obesity medicines|Anti-obesity]] · "Twincretin" |
| mechanism | String | Dual agonist of the [[GIP receptor]] and [[GLP-1 receptor]] ("twincretin"). |
| uses | String | [[Type 2 diabetes mellitus]] · [[Obesity]] · [[Obstructive sleep apnea]] in obesity |
| starting_dose | String | 2.5 mg SC weekly × 4 wk (non-therapeutic ramp)'"`UNIQ--ref-000002FB-QINU`"' |
| preparations | String | Pre-filled single-dose pen and vial: 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg'"`UNIQ--ref-000002FC-QINU`"''"`UNIQ--ref-000002FD-QINU`"' |
| fda_max | String | 15 mg/wk SC'"`UNIQ--ref-000002FE-QINU`"''"`UNIQ--ref-000002FF-QINU`"' |
| pill_id | Text | |
| routes | List of String, delimiter: , | Subcutaneous (abdomen • thigh • upper arm)'"`UNIQ--ref-00000300-QINU`"' |
| onset | String | Glycemic effect within days; full weight effect over months'"`UNIQ--ref-00000301-QINU`"' |
| duration | String | ~7 days (weekly dosing)'"`UNIQ--ref-00000302-QINU`"' |
| halflife | String | ~5 days (~120 h)'"`UNIQ--ref-00000303-QINU`"' |
| bioavailability | String | SC ~80%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| pregnancy | String | Avoid. Discontinue ≥1 month pre-conception. May reduce oral contraceptive efficacy during titration.'"`UNIQ--ref-00000304-QINU`"' |
| legal | String | Rx-only;'"`UNIQ--ref-00000305-QINU`"' not a controlled substance |
